🌍 Society & Frontier risk-on · 3–10 years
A what‑if from the future

What if Whole-genome screening at birth?

Cheap whole-genome sequencing becomes standard newborn care, shifting medicine toward prevention and personalized risk — a vast new data and care economy.

38%
our model probability
over 3–10 years
prediction markets — wisdom of the crowd
loading live odds…
Empirically anchored 38% · 90% range 11–64% · 13 analogues · measured class biotech 84% in 10 yr · 3% held back for the unknown
how we built this number — every step
Measured class rate — biotech ≈0.1843/yr → 84% in 10 yr84%
Analyst prior · editorial share 36% of the class30%
Pooled · weight 68%39%
Crowd — no liquid market
Reserve 3% · no extremizing (×1.0)39%
Published38%

The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.

The butterfly cascade

How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.

Resolution timeline — how this probability is moving

Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 3–10 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.

loading the timeline…

What it would mean

If this plays out, it is a risk-on shock. Cheap whole-genome sequencing becomes standard newborn care, shifting medicine toward prevention and personalized risk — a vast new data and care economy. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▲ · Longevity ▲ · Scientific breakthrough ▲ — which propagate through our causal graph to the markets below.

If it happens — the markets it would move

Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.

MarketClassProjected move
1Nasdaq 100 NDXon Hyperliquid 📈 chartIndex▲ +0.5%
hist +0.09–+0.53% · other way +0.36% (n=12)
2S&P 500 SPXon Hyperliquid 📈 chartIndex▲ +0.3%
hist -0.1–+0.56% · other way -2.38% (n=12)
3MicroStrategy MSTRon Hyperliquid 📈 chartEquity▲ +0.3%
hist -9.28–+14.2% · other way +11.19% (n=12)
4Tech sector XLK 📈 chartEquity▲ +0.3%
hist -0.38–+0.91% · other way +0.25% (n=12)
5Solana SOLon Hyperliquid 📈 chartCrypto▲ +0.3%
hist -9.21–+4.73% · other way -4.42% (n=11)
6Hyperliquid (HYPE) HYPEon HyperliquidCrypto▲ +0.2%
model prior · unmeasured
7Ether ETHon Hyperliquid 📈 chartCrypto▲ +0.2%
hist -2.17–+2.07% · other way -5.47% (n=12)
8Bitcoin BTCon Hyperliquid 📈 chartCrypto▲ +0.2%
hist -4.25–+6.96% · other way -1.09% (n=12)
9Volatility (VIX) VIXon Hyperliquid 📈 chartVol▼ -0.2%
hist -2.02–+2.37% · other way +9.33% (n=12)

Probable recommendation

If the scenario above plays out, the probable cross‑asset positioning → a scenario‑conditional read, not personalized investment advice
For a common-man portfolio: A typical stock-heavy portfolio should benefit. Stay invested; you can lean modestly into the beneficiaries below.
Also moves (not yet on Hyperliquid): Tech sector +0.3%

Historical precedent — what analogous events actually did

Across 13 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.

Wegovy 2021-06 First mRNA COVID-19 vaccine authorized 2020-12 Casgevy — first CRISPR gene-editing medicine approved 2023-12 mRNA pioneers win the Nobel 2023-10 First genetically-modified pig-to-human heart transplant 2022-01 AlphaFold cracks the protein-folding problem 2020-11 Human Genome Project completed 2003-04 Neuralink implants its first human brain-computer interface 2024-01 LK-99 room-temperature superconductor claim 2023-07 OpenAI releases GPT-4 2023-03 NIF achieves fusion ignition 2022-12 AlphaGo defeats Lee Sedol 2016-03 SpaceX lands an orbital rocket booster 2015-12
AssetHistory saysAbnormal (20d · 5d)HitnConfidencevs cascade
SOL SOLSHORT-9.2% · 5d -9.6%79%10 0.43⚠ differs
SPX SPXLONG+0.4% · 5d +1.0%66%13 0.29✓ matches cascade
US dollar DXYSHORT-0.6% · 5d -0.6%69%13 0.28·
Bitcoin BTCLONG+7.0% · 5d -5.3% ↺ fades62%12 0.23✓ matches cascade
High-yield credit HYGSHORT-0.1% · 5d -0.2%62%12 0.15·
MSTR MSTRLONG+14.6% · 5d +0.1%57%13 0.13✓ matches cascade
Gold XAULONG+0.9% · 5d +0.2%57%13 0.11·
NDX NDXLONG+0.2% · 5d -0.4% ↺ fades54%13 0.06✓ matches cascade
ETH ETHSHORT-2.5% · 5d -7.2%54%10 0.06⚠ differs
10y yield DGS10LONG+4bp · 5d 0bp ↺ fades54%13 0.06·
XLK XLKLONG+0.7% · 5d +0.0%51%13 0.02✓ matches cascade
Volatility VIXLONG+2.7% · 5d -3.4% ↺ fades49%13 0.00⚠ differs

Methodology. Probability and impact are anchored to history and scored against what actually happens — wins and losses, in public, at Reality Check. Crowd odds live from Polymarket & Kalshi. By Vikas Singh, Quantitative Strategist. Updated 2026-07-03.